Share
Every year, researchers at Massachusetts universities and academic medical centers make thousands of discoveries with the potential to become new products, technologies, and therapies. Some of those discoveries become the foundation of new companies, or academic spinouts. These companies are an important source of innovation, investment, and economic growth in the Commonwealth.
But turning a promising discovery into a successful company is extraordinarily difficult. There are countless scientific, technical, financial, and commercial challenges to overcome. Securing a license to the intellectual property (IP) underlying the technology shouldn't be one of them.
That's why Harvard University's recent launch of ExpressPath, a new approach to licensing university IP to startups, is an important development for the Massachusetts innovation ecosystem.
Removing Friction from Startup Formation
On October 15, Harvard's Office of Technology Development (OTD) introduced ExpressPath, offering standardized, non-negotiable startup licenses for three categories of innovation: Engineering & Technology, Medical Devices, and Software.
The program offers published, market-rate financial terms, benchmarked against approximately 1,800 licenses from peer universities, along with simplified license agreements. There are no upfront cash fees, patent expense reimbursement is deferred, and the business terms are established in advance.
The result is a licensing process that Harvard believes can be completed in days or weeks rather than the months traditionally required. "Simply put, ExpressPath removes the haggling," said Sam Liss, Harvard's Associate Provost and Chief Technology Development Officer.
That may sound like a relatively modest administrative improvement. In reality, it addresses one of the most persistent obstacles facing academic entrepreneurs.
University spinouts often confront a chicken-and-egg problem. Investors want to know that a company has secured the IP rights necessary to build its business before committing capital. Yet founders frequently need that capital to pay the legal expenses and other costs associated with negotiating a license. The process can consume months and tens of thousands of dollars before the company has even begun the hard work of commercialization. Speed matters.
By establishing clear, predictable terms at the outset, ExpressPath helps break that cycle. Founders can understand their obligations, investors can evaluate the economics, and everyone can focus on what matters most: building a viable company.
A Different Way to Think About Licensing
Beyond the immediate benefits of speed and lower transaction costs, ExpressPath represents something more significant: a shift in how we think about the objectives of university technology licensing.
Traditionally, academic IP licenses have often been approached as individual transactions, with considerable time and effort devoted to negotiating the financial terms of each deal. That approach makes sense for certain technologies, particularly those with established commercial value or complex licensing requirements.
But most academic spinouts begin with early-stage technologies whose ultimate commercial potential is highly uncertain. Even experienced investors struggle to predict which will succeed.
What if, instead of trying to optimize the financial return from every individual license, we focused on maximizing the number of well-prepared, adequately financed companies that have a realistic opportunity to succeed?
In venture investing, we understand the importance of taking more shots on goal. Every new company represents an opportunity to turn a promising idea into something meaningful, and some will go on to generate extraordinary returns, create entirely new industries, and transform people's lives.
The same principle applies to academic commercialization.
A licensing strategy that enables more promising technologies to reach the market can create greater long-term value than one focused primarily on optimizing the economics of each transaction. Successful spinouts can generate meaningful licensing income that benefits their inventors, originating laboratories, and institutions - helping fund future research - while also creating jobs, attracting private investment, and strengthening the broader innovation ecosystem.
This doesn't mean universities should give away their intellectual property or abandon their stewardship responsibilities. Quite the opposite. Licensing terms should be fair, financeable, and aligned with the long-term success of the company, while ensuring that institutions and inventors participate appropriately in the value they help create.
Nor does standardization eliminate the need for diligence. A license should go to a team with a credible commercialization plan, a commitment to developing the technology, and a realistic path to securing the resources needed to succeed.
Harvard's approach recognizes these distinctions. ExpressPath establishes a streamlined process for eligible startups while preserving traditional negotiated licensing for technologies and circumstances that warrant more individualized attention.
An Opportunity for Massachusetts
Massachusetts has one of the world's most productive academic research ecosystems. Our universities and academic medical centers collectively generate 90-100 new spinouts annually, according to data reported to the Association of University Technology Managers (AUTM).
These companies are an important engine of economic development. They attract investment, create high-quality jobs, bring new technologies to market, and help translate the Commonwealth's substantial investment in research into economic and societal benefits.
At MassVentures, we believe there is an opportunity to increase that number by making the path from academic discovery to startup formation more efficient, transparent, and predictable.
That mission has deep roots in the Commonwealth. In 2005, the Massachusetts Legislature established the Massachusetts Technology Transfer Center (MTTC) to accelerate the commercialization of research from the state's academic institutions. Today, that work continues through the Mass Academic Spinouts Center (MASC) at MassVentures, where we work with universities, investors, entrepreneurs, and other ecosystem partners to support the formation and growth of academic spinouts.
We were pleased to be among the investors and ecosystem participants Harvard consulted in developing and benchmarking its ExpressPath terms.
Harvard's leadership creates an important opportunity for other Massachusetts research institutions to examine their own licensing practices and consider where greater standardization, transparency, and alignment with startup financing could help more discoveries become companies.
There will always be technologies that require bespoke licensing arrangements. But not every academic spinout should have to begin its journey with months of negotiation over terms that could have been established in advance.
More Companies, More Opportunities
Launching a spinout is only the beginning. Founders still need to assemble capable teams, secure capital, demonstrate technical and commercial feasibility, and ultimately build products and services that customers want and investors will support.
ExpressPath doesn't eliminate those challenges. It removes an unnecessary obstacle to getting started.
We congratulate Sam Liss, the Harvard OTD team, and Harvard's leadership for taking this important step. Their willingness to rethink a longstanding process demonstrates how research institutions can play a more active role in enabling entrepreneurship.
The opportunity now is to build on that leadership across Massachusetts.
More promising discoveries reaching the market. More well-prepared founders pursuing ambitious ideas. More financeable spinouts with a genuine chance to succeed.
More shots on goal for Massachusetts innovation.
—-
Myron Kassaraba is Vice President, Investments at MassVentures and Director of the Mass Academic Spinouts Center (MASC).
Learn more about Harvard's ExpressPath licensing program.
Nov 12, 2026